Cargando…
Yields and product comparison between Escherichia coli BL21 and W3110 in industrially relevant conditions: anti-c-Met scFv as a case study
INTRODUCTION: In the biopharmaceutical industry, Escherichia coli is one of the preferred expression hosts for large-scale production of therapeutic proteins. Although increasing the product yield is important, product quality is a major factor in this industry because greatest productivity does not...
Autores principales: | Arauzo-Aguilera, Klaudia, Buscajoni, Luisa, Koch, Karin, Thompson, Gary, Robinson, Colin, Berkemeyer, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197847/ https://www.ncbi.nlm.nih.gov/pubmed/37208750 http://dx.doi.org/10.1186/s12934-023-02111-4 |
Ejemplares similares
-
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
por: Kang, Chung Hyo, et al.
Publicado: (2020) -
scFv Antibody: Principles and Clinical Application
por: Ahmad, Zuhaida Asra, et al.
Publicado: (2012) -
Nonspecificity in a nonimmune human scFv repertoire
por: Kelly, Ryan L., et al.
Publicado: (2017) -
“Stapling” scFv for multispecific biotherapeutics of superior properties
por: Boucher, Lauren E., et al.
Publicado: (2023) -
Isolation and characterization of human anti-CD20 single-chain variable fragment (scFv) from a Naive human scFv library
por: Shams, Nasir, et al.
Publicado: (2022)